CIK 0001706431 · Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812730369
- Phone
- 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-10-07 | Pang Phillip Chief Medical Officer | Sale | −5,000 | $41.73 | $209K | 29,777 |
| 2020-10-07 | Pang Phillip Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) | −10,185 | 100,461 | ||
| 2020-10-07 | Pang Phillip Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) | −2,315 | 50,927 | ||
| 2020-10-01 | Parrish Jay Chief Business Officer | Option exercise | +4,630 | $1.49 | $7K | 226,852 |
| 2020-10-01 | Parrish Jay Chief Business Officer | Option exercise | +2,315 | $1.58 | $4K | 229,167 |
| 2020-10-01 | Parrish Jay Chief Business Officer | Sale | −6,945 | $34.75 | $241K | 222,222 |
| 2020-10-01 | Parrish Jay Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −4,630 | 32,407 | ||
| 2020-10-01 | Parrish Jay Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −2,315 | 50,926 | ||
| 2020-09-29 | Virgin Herbert EVP, Research & CSO | Option exercise | +3,510 | $1.53 | $5K | 27,210 |
| 2020-09-29 | Virgin Herbert EVP, Research & CSO | Sale | −3,510 | $38.00 | $133K | 23,700 |
| 2020-09-29 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −3,510 | 459,875 | ||
| 2020-09-24 | Virgin Herbert EVP, Research & CSO | Option exercise | +3,700 | $1.53 | $6K | 23,700 |
| 2020-09-24 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −3,700 | 463,385 | ||
| 2020-09-22 | Virgin Herbert EVP, Research & CSO | Option exercise | +3,805 | $1.53 | $6K | 23,805 |
| 2020-09-22 | Virgin Herbert EVP, Research & CSO | Sale | −3,805 | $31.71 | $121K | 20,000 |
| 2020-09-22 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −3,805 | 467,085 | ||
| 2020-09-16 | Pang Phillip Chief Medical Officer | Option exercise | +9,720 | $1.58 | $15K | 39,497 |
| 2020-09-16 | Pang Phillip Chief Medical Officer | Option exercise | +465 | $1.53 | $711 | 39,962 |
| 2020-09-16 | Pang Phillip Chief Medical Officer | Option exercise | +2,315 | $5.18 | $12K | 42,277 |
| 2020-09-16 | Pang Phillip Chief Medical Officer | Sale | −7,500 | $31.88 | $239K | 34,777 |
Page 50 of 54 · 1,063 trades